Substance / Medication

Trimeprazine

Overview

Active Ingredient
trimeprazine
RxNorm CUI
10825

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer.
Kennett A, Hardy J, Shah S et al. · Support Care Cancer · 2005
PMID: 15700129Observational
Methotrimeprazine-Associated Stevens-Johnson Syndrome in 2 Ashkenazi Jewish Patients.
Moubayed Dina, Gifuni Anthony J, Tourian Leon · J Clin Psychopharmacol · 2017
PMID: 28027113Case Report
Symptom management using methotrimeprazine: expanding the definition of respite sedation.
Mazzotta Paolo · J Palliat Care · 2012
PMID: 22860387Case Report
Methotrimeprazine-induced corneal deposits and cataract revealed by urine drug profiling test.
Kim Seong Taeck, Koh Jae Woong, Kim Joon Mo et al. · J Korean Med Sci · 2010
PMID: 21060765Case ReportFull text (PMC)
High-dose levomepromazine (methotrimeprazine) to control nausea in carcinoid syndrome.
Amesbury Brendan, Alloway Lara, Hickmore Elizabeth et al. · J Palliat Care · 2004
PMID: 15332477Case Report
Trimeprazine is enantioselectively degraded by an activated sludge in ready biodegradability test conditions.
Escuder-Gilabert Laura, Martín-Biosca Yolanda, Perez-Baeza Mireia et al. · Water Res · 2018
PMID: 29775773Other
Methotrimeprazine for the management of end-of-life symptoms in infants and children.
Hohl Christopher M, Stenekes Simone, Harlos Michael S et al. · J Palliat Care · 2013
PMID: 24380217Other
Methotrimeprazine is a neuroprotective antiviral in JEV infection via adaptive ER stress and autophagy.
Prajapat Surendra K, Mishra Laxmi, Khera Sakshi et al. · EMBO Mol Med · 2024
PMID: 38177535PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Alimemazine (substance)
SNOMED CT
387471006
UMLS CUI
C0041031
RxNorm CUI
10825

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

5
Conditions
2
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.